Regeneron Announces Presentation at the UBS Global Life Sciences Conference

TARRYTOWN, N.Y., Sept. 13 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the UBS Global Life Sciences Conference on Monday, September 20, 2010.  The presentation is scheduled for 10:00 a.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through October 20, 2010.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Contact Information:


Michael Aberman, M.D.

Investor Relations

914.345.7799

[email protected]


Peter Dworkin

Corporate Communications

914.345.7800

[email protected]



SOURCE Regeneron Pharmaceuticals, Inc.

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.